45% EBITDA growth in FY24, EBITDA reaches USD 10 Bn Adani Portfolio EBITDA increased to USD…
Continue ReadingCategoría: Business Wire
Categoría agregada por el Plugin WPeMatico
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
DREAMM-8 phase III trial showed statistically significant and clinically meaningful improvement in primary endpoint of progression-free…
Continue Reading
Denodo Opens ME Regional Head Office in Kingdom of Saudi Arabia to Meet Growing Demand for Data Management and AI
At the office opening today, Ángel Viña, CEO of Denodo will be joined by Dr. Shaikha…
Continue Reading
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
57% of patients treated with IMFINZI were alive at three years in ADRIATIC Phase III trial…
Continue Reading
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
– In Cohort B of the ARC-9 mCRC Study, Etrumadenant Plus Zimberelimab, FOLFOX Chemotherapy and Bevacizumab…
Continue ReadingGilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
– In Cohort B of the ARC-9 mCRC Study, Etrumadenant Plus Zimberelimab, FOLFOX Chemotherapy and Bevacizumab…
Continue Reading
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
Initial data from the ongoing Phase 2 trial showed a 12-month overall survival (OS) rate of…
Continue Reading
“Experience the Luxury of Japanese Tradition and Cuisine” Reservations for the New Inbound Experience Tour in Osaka’s Tondabayashi Begin on June 1, 2024!
OSAKA, Japan–(BUSINESS WIRE)–The city of Tondabayashi in Osaka is excited to announce a new inbound tour…
Continue Reading
Tempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support Guideline-directed Biomarker Testing in NSCLC
CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its…
Continue Reading
Postmedia Announces Closing of Previously Announced Transaction with the Klein Group
TORONTO–(BUSINESS WIRE)–Postmedia Network Inc., a wholly owned subsidiary of Postmedia Network Canada Corp. (“Postmedia” or “the…
Continue Reading